Detalhe da pesquisa
1.
Daratumumab, carfilzomib, lenalidomide, and dexamethasone with tandem transplant for high-risk newly diagnosed myeloma.
Blood
; 143(20): 2029-2036, 2024 May 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-38394666
2.
RAS/RAFlandscape in monoclonal plasma cell conditions.
Blood
; 2024 Apr 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-38643494
3.
The location of the t(4;14) translocation breakpoint within the NSD2 gene identifies a subset of patients with high-risk NDMM.
Blood
; 141(13): 1574-1583, 2023 03 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-35984902
4.
High-dose melphalan treatment significantly increases mutational burden at relapse in multiple myeloma.
Blood
; 141(14): 1724-1736, 2023 04 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36603186
5.
Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del(1p32) remains a strong prognostic factor.
Blood
; 141(11): 1308-1315, 2023 03 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-36375118
6.
SAR442085, a novel anti-CD38 antibody with enhanced antitumor activity against multiple myeloma.
Blood
; 139(8): 1160-1176, 2022 02 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-35201323
7.
Primary plasma cell leukemias displaying t(11;14) have specific genomic, transcriptional, and clinical features.
Blood
; 139(17): 2666-2672, 2022 04 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-35171994
8.
Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma in real-world: The retrospective IMAGE study.
Eur J Haematol
; 2024 May 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-38712850
9.
Risk factors in multiple myeloma: is it time for a revision?
Blood
; 137(1): 16-19, 2021 01 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33024991
10.
IgM-MM is predominantly a pre-germinal center disorder and has a distinct genomic and transcriptomic signature from WM.
Blood
; 138(20): 1980-1985, 2021 11 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-34792571
11.
Up-front carfilzomib, lenalidomide, and dexamethasone with transplant for patients with multiple myeloma: the IFM KRd final results.
Blood
; 138(2): 113-121, 2021 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33827114
12.
del(17p) without TP53 mutation confers a poor prognosis in intensively treated newly diagnosed patients with multiple myeloma.
Blood
; 137(9): 1192-1195, 2021 03 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33080624
13.
Heterogeneity in long-term outcomes for patients with Revised International Staging System stage II, newly diagnosed multiple myeloma.
Haematologica
; 108(5): 1374-1384, 2023 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36172814
14.
Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial.
Lancet Oncol
; 22(10): 1378-1390, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34529931
15.
Multiple Myeloma Minimal Residual Disease Detection: Targeted Mass Spectrometry in Blood vs Next-Generation Sequencing in Bone Marrow.
Clin Chem
; 67(12): 1689-1698, 2021 11 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-34643690
16.
High subclonal fraction of 17p deletion is associated with poor prognosis in multiple myeloma.
Blood
; 133(11): 1217-1221, 2019 03 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-30692124
17.
Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study.
Lancet
; 394(10192): 29-38, 2019 07 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31171419
18.
Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma.
Blood
; 132(23): 2456-2464, 2018 12 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-30249784
19.
Imprinting of Mesenchymal Stromal Cell Transcriptome Persists even after Treatment in Patients with Multiple Myeloma.
Int J Mol Sci
; 21(11)2020 May 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-32481768
20.
To be hematopoietic, or not to be: That is the neoplastic cell's question.
Am J Hematol
; 99(4): 719-720, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-37815478